GSK Earnings: Strong Start to the Year Due to Specialty Medicines and Shingrix

In the quarter, GSK reported 5% year-over-year earnings growth at constant currency and core operating margin of 34.7%, a 1.8-percentage-point improvement over the same period last year. Management also reaffirmed full-year guidance of 3%-5% sales growth and 7%-9% core EPS growth.